Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating Investment IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Cardiol Therapeutics (CRDL) Other Non Operating Income (2020 - 2026)

Cardiol Therapeutics filings provide 2 years of Other Non Operating Income readings, the most recent being -$389210.5 for Q4 2022.

  • On a quarterly basis, Other Non Operating Income fell 110.01% to -$389210.5 in Q4 2022 year-over-year; TTM through Dec 2022 was $2.1 million, a 45.29% decrease, with the full-year FY2025 number at $681182.9, up 291.57% from a year prior.
  • Other Non Operating Income hit -$389210.5 in Q4 2022 for Cardiol Therapeutics, down from $2.3 million in the prior quarter.
  • In the past five years, Other Non Operating Income ranged from a high of $3.9 million in Q4 2021 to a low of -$1.1 million in Q1 2022.